A Food & Drug Administration panel approved a Boston Scientific Corp. (NYSE:BSX) bid to expand the indication of its cardiac resynchronization therapy defibrillators to cover patients suffering from milder forms of heart failure.
The decision from the FDA’s circulatory systems devices panel came late Thursday afternoon. The company’s current indication is for patients diagnosed with New York Heart Assn. Class III or Class IV heart failure, classified as the most severe cases. An expanded indication opens up a significant new market opportunity for BSX, according to company officials.
It’s a much-needed boost for for Boston Scientific’s cardiac rhythm management business as it struggles through a rough week. The company voluntarily stopped all shipments of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators and pulled its inventory from the field after discovering that it missed a pair of filings with the FDA.
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
News reports estimate that the hold could last as long as a month as BSX files for a 30-day supplement to its pre-market approval from regulators to clear up the paperwork issue. Agency officials have said they are not aware of any safety concerns regarding the devices.
The approved expansion of the CRT-D indication seemed likely March 16, when an FDA panel released a report generally supportive of the Natick, Mass.-based medical device giant’s Madit-CRT study last fall, writing that it provided sound evidence of the devices’ effectiveness in reducing heart failure events during a clinical trial that involved more than 1,800 patients.
The panel was less certain about the overall benefits to a wider patient population suffering from milder forms of heart failure. But it was evidently satisfied with the answers given by the company today and chose to rule in its favor.
MedCity News Pivot Podcast: How Emergency Departments Are Using Real-Time Data to Improve Outcomes
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.